Cargando…
Case Report: Treatment of systemic mastocytosis with sunitinib
Mast cell activation disease typically presents as chronic multisystem polymorbidity of generally inflammatory ± allergic theme. Presently, treatment of the rare, cytoproliferative variant systemic mastocytosis employs empirically selected therapies to impede mast cell mediator production and actio...
Autores principales: | Molderings, Gerhard J., Afrin, Lawrence B., Hertfelder, Hans-Jörg, Brettner, Stefan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
F1000 Research Limited
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5946163/ https://www.ncbi.nlm.nih.gov/pubmed/29770197 http://dx.doi.org/10.12688/f1000research.13343.1 |
Ejemplares similares
-
Determination of Plasma Heparin Level Improves Identification of Systemic Mast Cell Activation Disease
por: Vysniauskaite, Milda, et al.
Publicado: (2015) -
Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options
por: Molderings, Gerhard J, et al.
Publicado: (2011) -
Effects of Primary Mast Cell Disease on Hemostasis and Erythropoiesis
por: Seidel, Holger, et al.
Publicado: (2021) -
Pharmacological treatment options for mast cell activation disease
por: Molderings, Gerhard J., et al.
Publicado: (2016) -
Oral and inhaled sodium cromoglicate in the management of systemic mastocytosis: a case report
por: Edwards, Alan M, et al.
Publicado: (2010)